Prognostic factors and Doxorubicin involved in malignant progression of meningioma

Meningioma was the most primary intracranial tumor, but the molecular characteristics and the treatment of malignant meningioma were still unclear. Nine malignant progression-related genes based prognostic signatures were identified by transcriptome analysis between benign meningioma and malignant m...

Descripción completa

Detalles Bibliográficos
Autores principales: Huo, Xulei, Song, Lairong, Wang, Ke, Wang, Hongyi, Li, Da, Li, Huan, Wang, Wei, Wang, Yali, Chen, Lei, Zhao, Zongmao, Wang, Liang, Wu, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079659/
https://www.ncbi.nlm.nih.gov/pubmed/37024523
http://dx.doi.org/10.1038/s41598-023-28996-0
_version_ 1785020757078704128
author Huo, Xulei
Song, Lairong
Wang, Ke
Wang, Hongyi
Li, Da
Li, Huan
Wang, Wei
Wang, Yali
Chen, Lei
Zhao, Zongmao
Wang, Liang
Wu, Zhen
author_facet Huo, Xulei
Song, Lairong
Wang, Ke
Wang, Hongyi
Li, Da
Li, Huan
Wang, Wei
Wang, Yali
Chen, Lei
Zhao, Zongmao
Wang, Liang
Wu, Zhen
author_sort Huo, Xulei
collection PubMed
description Meningioma was the most primary intracranial tumor, but the molecular characteristics and the treatment of malignant meningioma were still unclear. Nine malignant progression-related genes based prognostic signatures were identified by transcriptome analysis between benign meningioma and malignant meningioma. The external dataset GEO136661 and quantitative Real-time Polymerase Chain Reaction were used to verify the prognostic factors. has-miR-3605-5p, hsa-miR-664b-5p, PNRC2, BTBD8, EXTL2, SLFN13, DGKD, NSD2, and BVES were closed with malignant progression. Moreover, Doxorubicin was identified by Connectivity Map website with the differential malignant progression-related genes. CCK-8 assay, Edu assay, wound healing assay, and trans-well experiment were used to reveal that Doxorubicin could inhibit proliferation, migration and invasion of IOMM-Lee Cells.
format Online
Article
Text
id pubmed-10079659
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-100796592023-04-08 Prognostic factors and Doxorubicin involved in malignant progression of meningioma Huo, Xulei Song, Lairong Wang, Ke Wang, Hongyi Li, Da Li, Huan Wang, Wei Wang, Yali Chen, Lei Zhao, Zongmao Wang, Liang Wu, Zhen Sci Rep Article Meningioma was the most primary intracranial tumor, but the molecular characteristics and the treatment of malignant meningioma were still unclear. Nine malignant progression-related genes based prognostic signatures were identified by transcriptome analysis between benign meningioma and malignant meningioma. The external dataset GEO136661 and quantitative Real-time Polymerase Chain Reaction were used to verify the prognostic factors. has-miR-3605-5p, hsa-miR-664b-5p, PNRC2, BTBD8, EXTL2, SLFN13, DGKD, NSD2, and BVES were closed with malignant progression. Moreover, Doxorubicin was identified by Connectivity Map website with the differential malignant progression-related genes. CCK-8 assay, Edu assay, wound healing assay, and trans-well experiment were used to reveal that Doxorubicin could inhibit proliferation, migration and invasion of IOMM-Lee Cells. Nature Publishing Group UK 2023-04-06 /pmc/articles/PMC10079659/ /pubmed/37024523 http://dx.doi.org/10.1038/s41598-023-28996-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Huo, Xulei
Song, Lairong
Wang, Ke
Wang, Hongyi
Li, Da
Li, Huan
Wang, Wei
Wang, Yali
Chen, Lei
Zhao, Zongmao
Wang, Liang
Wu, Zhen
Prognostic factors and Doxorubicin involved in malignant progression of meningioma
title Prognostic factors and Doxorubicin involved in malignant progression of meningioma
title_full Prognostic factors and Doxorubicin involved in malignant progression of meningioma
title_fullStr Prognostic factors and Doxorubicin involved in malignant progression of meningioma
title_full_unstemmed Prognostic factors and Doxorubicin involved in malignant progression of meningioma
title_short Prognostic factors and Doxorubicin involved in malignant progression of meningioma
title_sort prognostic factors and doxorubicin involved in malignant progression of meningioma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079659/
https://www.ncbi.nlm.nih.gov/pubmed/37024523
http://dx.doi.org/10.1038/s41598-023-28996-0
work_keys_str_mv AT huoxulei prognosticfactorsanddoxorubicininvolvedinmalignantprogressionofmeningioma
AT songlairong prognosticfactorsanddoxorubicininvolvedinmalignantprogressionofmeningioma
AT wangke prognosticfactorsanddoxorubicininvolvedinmalignantprogressionofmeningioma
AT wanghongyi prognosticfactorsanddoxorubicininvolvedinmalignantprogressionofmeningioma
AT lida prognosticfactorsanddoxorubicininvolvedinmalignantprogressionofmeningioma
AT lihuan prognosticfactorsanddoxorubicininvolvedinmalignantprogressionofmeningioma
AT wangwei prognosticfactorsanddoxorubicininvolvedinmalignantprogressionofmeningioma
AT wangyali prognosticfactorsanddoxorubicininvolvedinmalignantprogressionofmeningioma
AT chenlei prognosticfactorsanddoxorubicininvolvedinmalignantprogressionofmeningioma
AT zhaozongmao prognosticfactorsanddoxorubicininvolvedinmalignantprogressionofmeningioma
AT wangliang prognosticfactorsanddoxorubicininvolvedinmalignantprogressionofmeningioma
AT wuzhen prognosticfactorsanddoxorubicininvolvedinmalignantprogressionofmeningioma

Ejemplares similares